9780323884594 - essentials of translational pediatric drug development: from past needs to future opportunities (3 Ergebnisse)
- Softcover
Anbieter: Majestic Books, Hounslow, , Vereinigtes KönigreichMajestic Books
Verkäufer/-in kontaktierenVerkäufer/-in mit 4 SternenZustand: Neu
EUR 155,66
EUR 7,53 VersandVersand von Vereinigtes Königreich nach USAAnzahl: 3 verfügbar
Zustand: New.
Essentials of Translational Pediatric Drug Development: From Past Needs to Future Opportunities
Gasthuys, Elke (Editor)/ Allegaert, Karel (Editor)/ Dossche, Lien (Editor)/ Turner, Mark (Editor)
- Softcover
Anbieter: Revaluation Books, Exeter, , Vereinigtes KönigreichRevaluation Books
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 159,36
EUR 17,39 VersandVersand von Vereinigtes Königreich nach USAAnzahl: 2 verfügbar
Paperback. Zustand: Brand New. 670 pages. 9.25x7.50x9.00 inches. In Stock.
- Softcover
Anbieter: Buchpark, Trebbin, , DeutschlandBuchpark
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Gebraucht
EUR 91,35
EUR 105,00 VersandVersand von Deutschland nach USAAnzahl: 1 verfügbar
Zustand: Hervorragend. Zustand: Hervorragend | Seiten: 728 | Sprache: Englisch | Produktart: Bücher | Essentials of Translational Pediatric Drug Development: From Past Needs to Future Opportunities provides integrated and up-to-date insights relevant for both translational researchers and clinicians active in the field of pediat…ric drug development. The book covers all key aspects from different stakeholder perspectives, providing a literature overview and careful reflection on state-of-the-art approaches. It will be an ideal guide for researchers in the field who are designing and performing high quality, innovative pediatric-adapted drug development by helping them define needs/challenges and possible solutions that advance and harmonize pediatric drug development. Despite the broad consensus that children merit the same quality of drug treatment as any other age group, children remain frequently neglected during drug research and development. Even with the adoption of multiple legislations addressing this problem, the lack of efficacy and safety data of marketed as well as newly developed drugs still remain in the pediatric population.
